Abstract
Antibodies are the largest class of biotherapeutics. However, in recent years, single-domain antibodies have gained traction due to their smaller size and comparable binding affinity. Antibodies (Abs) and single-domain antibodies (sdAbs) differ in the structures of their binding sites: most significantly, single-domain antibodies lack a light chain and so have just three CDR loops. Given this inherent structural difference, it is important to understand whether Abs and sdAbs are distinguishable in how they engage a binding partner and thus, whether they are suited to different types of epitopes. In this study, we use non-redundant sequence and structural datasets to compare the paratopes, epitopes and antigen interactions of Abs and sdAbs. We demonstrate that even though sd-Abs have smaller paratopes, they target epitopes of equal size to those targeted by Abs. To achieve this, the paratopes of sdAbs contribute more interactions per residue than the paratopes of Abs. Additionally, we find that conserved framework residues are of increased importance in the paratopes of sd-Abs, suggesting that they include non-specific interactions to achieve comparable affinity. Furthermore, the epitopes of sdAbs and Abs cannot be distinguished by their shape. For our datasets, sd-Abs do not target more concave epitopes than Abs: we posit that this may be explained by differences in the orientation and compaction of sdAb and Ab CDR-H3 loops. Overall, our results have important implications for the engineering and humanization of sdAbs, as well as the selection of the best modality for targeting a particular epitope.
Introduction
Antibodies (Abs) are established leaders in biotherapeutics, but their large size (~150kDa) can limit tissue penetration and increase production costs. Single-domain antibodies (sdAbs or nanobodies), derived from camelid heavy-chain-only antibodies, offer a compact alternative at roughly a tenth of the size (~15kDa) while maintaining high binding affinity.
A fundamental structural difference between the two is the absence of a light chain in sdAbs, leaving them with only three complementarity-determining region (CDR) loops compared to the six found in traditional Abs. A long-standing hypothesis suggested that sdAbs compensate for this by utilizing longer CDR-H3 loops to reach into concave epitopes, such as enzyme active sites, that are inaccessible to bulkier antibodies. This study performs a large-scale structural comparison to determine if sdAbs and Abs truly target different "epitope spaces" or if they simply employ different structural strategies to bind similar targets.
Methods and Datasets
The researchers utilized a comprehensive bioinformatics approach, drawing from high-quality repositories including SAbDab and SAbDab-nano for structural complexes, and the Observed Antibody Space (OAS) for large-scale sequence data.
Key methodologies included:
- Structural Analysis: Comparing 892 Ab-Ag and 345 sdAb-Ag non-redundant crystal complexes.
- Interaction Mapping: Using the Arpeggio tool to calculate interatomic contacts (e.g., van der Waals, hydrogen bonds) to determine interaction density.
- Geometric Characterization: Quantifying epitope concavity and convexity using "alpha shapes" and vertex defect calculations.
- Orientation Descriptors: Applying spherical coordinates to describe the reach and compaction of the CDR-H3 loop relative to the antibody framework.
Strict redundancy filters (95% sequence identity) and resolution limits (≤ 3.0Å) were applied to ensure unbiased results.
Results and Discussion
Paratope and Epitope Characteristics
Analysis revealed that sdAb paratopes are significantly smaller than those of traditional Abs, typically by 2.6 to 3.6 residues. Despite this reduction in binding site size, there was no significant difference in the size of the epitopes targeted; sdAbs contact a similar number of antigen residues as traditional Abs.
To compensate for their smaller paratopes, sdAbs exhibit higher "efficiency per residue," showing a mean increase of 0.19 interactions per residue compared to Abs. Furthermore, sdAbs rely more heavily on conserved framework regions for binding, suggesting that these regions provide critical non-specific interactions to maintain high affinity.
The CDR-H3 Loop and the "Concavity Myth"
One of the most significant findings is the debunking of the "concavity myth." Statistical analysis of epitope shapes (mean vertex defect) showed no significant difference (p-value = 0.13) between the two modalities. While sdAbs do possess CDR-H3 loops that are, on average, 1.4 to 1.6 residues longer than those in traditional Abs, these loops do not necessarily "reach" further.
The data suggests that sdAb CDR-H3 loops are often more compacted or folded back against the VH domain. In contrast, the presence of a light chain in traditional Abs can force the CDR-H3 to orient outward, sometimes granting it a greater effective reach despite a shorter sequence length.
Conclusion
This study demonstrates that sdAbs and Abs target a statistically indistinguishable epitope shape space. The unique advantages of sdAbs likely stem from their smaller overall footprint and increased interaction density rather than a specialized ability to target concave surfaces. These insights have immediate implications for antibody engineering; specifically, the increased reliance on framework residues in sdAbs suggests that humanization efforts must be careful not to disrupt these critical, though non-CDR, binding components. Future research may explore whether this reliance on conserved framework residues impacts the overall specificity or cross-reactivity of single-domain antibodies.
Summary updated